Life Sciences Venture Investments Still Have a Pulse

Several leading hedge funds specializing in life sciences and biopharma have been more active in the private markets this quarter. But overall volume is still way down from the highs.

Carsten Snejbjerg/Bloomberg

Carsten Snejbjerg/Bloomberg

Life sciences and biopharma hedge fund firms ramped up their venture capital activity in the first quarter, after most of them sharply pulled back in the three months ending in December.

Even so, the number of private investments is still way behind the pace set during the first three quarters of 2021, when the IPO market was red hot.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.